502 Applying Landmark DECLARE, DAPA-CKD, DAPA-HF and DELIVER Trial Findings in US Adults with Cardiometabolic and Renal Diseases: Medical Care Cost-Offsets Associated with Dapagliflozin compared to Standard of Care